hard reset sinuva fear earli launch
glitch may turn deeper defect
follow morn earli earn announc manag
discuss issu underli weak report reduc sale
guidanc troubl us instead sinuva easili
avail via specialti pharmaci channel mani payor requir
doctor either use payor-affili specialti pharmaci partner
use buy-and-bil approach mean doctor must pay acquir
sinuva bill hope paid back management
believ hurdl overcom show reluct doc proof
payment expand salesforc think difficult
chang way ent oper cut sinuva sale estim
beyond also dampen model growth rate propel
expect sinuva avail via specialti pharmaci
channel includ support bill adjud etc instead
reason unclear us certain payor requir buy-and-
bill co intend use explan benefit eob form
doctor receiv payment help convinc ent tri
buy-and-bil approach think ent may want risk spend
sinuva without certainti around payment management note
overal submit sinuva claim
approv line intern expect
support role ad xent salesforc
see invest enabl acceler sinuva sale
model steep increas oper spend percentag revenu
back half year
management reiter confid would grant sinuva
product-specif code novemb effect januari
less certain remain concern could present
anoth hurdl sinuva adopt come quarter
valuat rate neutral risk discuss
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
significantli reduc sale estim sinuva beyond
less optimist manag think hurdl around
launch physician wari buy-and-bil approach potenti
less-than-favor decis novemb may limit product appeal
also cut outlook core propel busi model revenu
lower end revis guidanc rang
model sinuva sale y/i growth propel
dampen sinuva sale ramp extend forecast well
 lower increas oper spend model near
top end oper expens guidanc longer model
turn profit horizon model
intersect ent rate neutral intersect primarili valu sale
growth trade ntm ev/sal estim comp
group feel fair light reduc guidanc
complex around sinuva launch btig provid price target
neutral-r stock risk rate includ product access issu
payer pushback advers event relat product
btig estim compani filingsnewold changentm medicalwmginot factset data btig estim intra-day price ptprice market cap bp/e ex-amortev/salescagr
incom etot y/i sale oper incom incom tax expens incom share oper expens btig estim compani report
revenu etot propel/contour y/i propel/contour y/i y/i propel/contour q/q propel/contour q/q q/q per unit sold per unit sold per per unit sold sale rep etot distribut rep rep rep month rep btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
